Loading…
Reported covered position: Secr for Congr & Intgv Affairs, Dept. Labor 01-02
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013.
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2014 · third_quarter · Q3
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE, Treasury, Dept of
Source: Senate LDA
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2725- FDA Safety Over Sequestration Act
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2725- FDA Safety Over Sequestration Act
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013.
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013.
Ending Special Mail Privileges for Congress Act of 2014
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
Ending Special Mail Privileges for Congress Act of 2014
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
Ending Special Mail Privileges for Congress Act of 2014
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
H.R. 3590 - Patient Protection and Affordable Care Act (implementation) H.R. 4872 - Health Care and Education Reconciliation Act (implementation)
Ending Special Mail Privileges for Congress Act of 2014
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
H.R. 3590 - Patient Protection and Affordable Care Act (implementation) H.R. 4872 - Health Care and Education Reconciliation Act (implementation)
Protect Medical Innovation Act of 2013
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
The Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act relating to delay of the ACA medical device tax; S. 232 - Medical Device Access and Innovation Protection Act; H.R. 523 - Protect Medical Innovation Act
Medical Device Access and Innovation Protection Act
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
The Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act relating to delay of the ACA medical device tax; S. 232 Medical Device Access and Innovation Protection Act.
Medical Device Access and Innovation Protection Act
Client: ROCHE DIAGNOSTICS CORPORATION · Firm: BROWN RUDNICK LLP
The Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act relating to delay of the ACA medical device tax; S. 232 - Medical Device Access and Innovation Protection Act; H.R. 523 - Protect Medical Innovation Act
Indonesian Family Refugee Protection Act
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
H.R. 3590 - Patient Protection and Affordable Care Act (implementation) H.R. 4872 - Health Care and Education Reconciliation Act (implementation)
Indonesian Family Refugee Protection Act
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
Indonesian Family Refugee Protection Act
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
H.R. 3590 - Patient Protection and Affordable Care Act (implementation) H.R. 4872 - Health Care and Education Reconciliation Act (implementation)
Indonesian Family Refugee Protection Act
Client: NATIONAL ASSOCIATION OF DENTAL PLANS · Firm: BROWN RUDNICK LLP
H.R. 3590 - Patient Protection and Affordable Care Act (implementation and related regulations) H.R. 4872 - Health Care and Education Reconciliation Act (implementation and related regulations)
Safeguarding America's Pharmaceuticals Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013; S. 957 The Drug Supply Chain Security Act.
Safeguarding America's Pharmaceuticals Act of 2013
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
Issues relating to prescription drug shortages: --P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products.; --H.R. 1919: Safeguarding America's Pharmaceuticals Act of 2013; --H.R. 3204: The Drug Quality and Safety Act; --S. 957: The Drug Supply Chain Security Act; --S. 232: Medical Device Access and Innovation Protection Act
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
-- S. 1413: FDA User Fee Protection Act -- H.R. 2725: "FDA Safety Over Sequestration Act of 2013
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 2725: FDA Safety Over Sequestration Act of 2013
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2725 - FDA Safety over Sequestration Act. Biosimilar implementation -Track and trace legislation
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2725 - FDA Safety over Sequestration Act. Biosimilar implementation -Track and trace legislation
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2725 - FDA Safety over Sequestration Act. Biosimilar implementation -Track and trace legislation
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2725- FDA Safety Over Sequestration Act; S. 1413 FDA User Fee Protection Act.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
H.R. 2725 - FDA Safety over Sequestration Act. Biosimilar implementation -Track and trace legislation
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013; S. 957 The Drug Supply Chain Security Act.
Issues relating to prescription drug shortages: --P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products.; --H.R. 1919: Safeguarding America's Pharmaceuticals Act of 2013; --H.R. 3204: The Drug Quality and Safety Act; --S. 957: The Drug Supply Chain Security Act; --S. 232: Medical Device Access and Innovation Protection Act
-- Issues relating to generic drug labeling -- S. 959: The Pharmaceutical Quality, Security and Accountability Act -- H.R. 3204: The Compounding Clarity Act
Issues relating to generic drug labeling; S. 959: The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act
S. 959 The Phamaceutical Quality, Security & Accountability Act; H.R. 3204 The Compounding Clarity Act; Issues related to FDA rule on drug labeling.
H.R. 3204: The Drug Quality and Safety Act S. 959: The Pharmaceutical Quality, Security and Accountability Act
S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
-- S. 1413: FDA User Fee Protection Act -- H.R. 2725: "FDA Safety Over Sequestration Act of 2013
H.R. 2725- FDA Safety Over Sequestration Act; S. 1413 FDA User Fee Protection Act.
Preserve Access to Affordable Generics Act
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
S. 504: Fair and Immediate Release of Generic Drugs Act S. 214: Preserve Access to Affordable Generics Act Issues relating to Risk Evaluation and Mitigation Strategies and implementation of the Generic Drug User Fee Act
Preserve Access to Affordable Generics Act
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
S. 504: Fair and Immediate Release of Generic Drugs Act S. 214: Preserve Access to Affordable Generics Act
Medical Device Access and Innovation Protection Act
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
Issues relating to prescription drug shortages: --P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products.; --H.R. 1919: Safeguarding America's Pharmaceuticals Act of 2013; --H.R. 3204: The Drug Quality and Safety Act; --S. 957: The Drug Supply Chain Security Act; --S. 232: Medical Device Access and Innovation Protection Act
Medical Device Access and Innovation Protection Act
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
Issues relating to drug and nutrient shortages; P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 232: Medical Device Access and Innovation Protection Act
S. 504: Fair and Immediate Release of Generic Drugs Act S. 214: Preserve Access to Affordable Generics Act
S. 504: Fair and Immediate Release of Generic Drugs Act S. 214: Preserve Access to Affordable Generics Act Issues relating to Risk Evaluation and Mitigation Strategies and implementation of the Generic Drug User Fee Act
Issues relating to prescription drug shortages: --P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products.; --H.R. 1919: Safeguarding America's Pharmaceuticals Act of 2013; --H.R. 3204: The Drug Quality and Safety Act; --S. 957: The Drug Supply Chain Security Act; --S. 232: Medical Device Access and Innovation Protection Act
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013; S. 957 The Drug Supply Chain Security Act.
Pharmaceutical Quality, Security, and Accountability Act
Client: APOTEX CORPORATION · Firm: BROWN RUDNICK LLP
H.R. 3204: The Drug Quality and Safety Act S. 959: The Pharmaceutical Quality, Security and Accountability Act
Pharmaceutical Quality, Security, and Accountability Act
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
-- Issues relating to generic drug labeling -- S. 959: The Pharmaceutical Quality, Security and Accountability Act -- H.R. 3204: The Compounding Clarity Act
Pharmaceutical Quality, Security, and Accountability Act
Client: HOSPIRA, INC. · Firm: BROWN RUDNICK LLP
Issues relating to generic drug labeling; S. 959: The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act
Pharmaceutical Quality, Security, and Accountability Act
Client: AMNEAL PHARMACEUTICALS · Firm: BROWN RUDNICK LLP
S. 959 The Phamaceutical Quality, Security & Accountability Act; H.R. 3204 The Compounding Clarity Act; Issues related to FDA rule on drug labeling.
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2014 · third_quarter · Q3
The Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act relating to delay of the ACA medical device tax; S. 232 - Medical Device Access and Innovation Protection Act; H.R. 523 - Protect Medical Innovation Act
Issues relating to diagnostic laboratory testing
HPV primary screening application
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2014 · third_quarter · Q3
Issues relating to Risk Evaluation and Mitigation Strategy programs; Generic Drug User Fee Amendments of 2012 (GDUFA); Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2014 · third_quarter · Q3
Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming and reimbursement.
Issues relating to drug shortages; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2014 · third_quarter · Q3
Implementation of P.L. 112-144 (FDA Safety and Innovation Act) and P.L. 113 - 54 (Drug Quality and Security Act); Issues relating to ANDA approval
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2014 · third_quarter · 3A
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); P.L. 110 -85 relating to Risk Evaluation and Mitigation Strategy programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2014 · third_quarter · Q3
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); P.L. 110 -85 relating to Risk Evaluation and Mitigation Strategy programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EXELA HOLDINGS, LLC via BROWN RUDNICK LLP
2014 · second_quarter · Q2
Issues relating to drug compounding - Public Law 113-54
Issues relating to drug shortage - Public Law No: 112-144, FDA Safety and Innovation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2014 · second_quarter · Q2
The Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act relating to delay of the ACA medical device tax; S. 232 Medical Device Access and Innovation Protection Act.
HPV primary screening application
Issues relating to diagnostic laboratory testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2014 · second_quarter · Q2
H.R. 3590 - Patient Protection and Affordable Care Act (implementation) H.R. 4872 - Health Care and Education Reconciliation Act (implementation)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2014 · second_quarter · Q2
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013.
Issues related to FDA rule on drug labeling; issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).
H.R. 2725- FDA Safety Over Sequestration Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2014 · second_quarter · Q2
Issues relating to drug shortages, patent use codes and drug labeling (RIN:0910-AG94: FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products)
Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming. Issues relating to opiate overdosing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
APOTEX CORPORATION via BROWN RUDNICK LLP
2014 · second_quarter · Q2
Issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2014 · first_quarter · Q1
Issues relating to opiate overdosing.
Issues relating to drug shortages, patent use codes and drug labeling (RIN:0910-AG94: FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
NATIONAL ASSOCIATION OF DENTAL PLANS via BROWN RUDNICK LLP
2014 · first_quarter · Q1
H.R. 3590 - Patient Protection and Affordable Care Act (implementation) H.R. 4872 - Health Care and Education Reconciliation Act (implementation)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2014 · first_quarter · Q1
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013.
Issues related to FDA rule on drug labeling; issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).
H.R. 2725- FDA Safety Over Sequestration Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2014 · first_quarter · Q1
The Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act relating to delay of the ACA medical device tax.
Issues relating to diagnostic laboratory testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2014 · first_quarter · Q1
Fair and Immediate Release of Generic Drugs Act and Preserve Access to Affordable Generics Act
Issues relating to Risk Evaluation and Mitigation Strategies; Drug Quality and Security Act ( P.L. 113-54); FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (RIN:0910-AG94).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2013 · fourth_quarter · Q4
H.R. 2725- FDA Safety Over Sequestration Act; S. 1413 FDA User Fee Protection Act.
S. 959 The Phamaceutical Quality, Security & Accountability Act; H.R. 3204 The Compounding Clarity Act; Issues related to FDA rule on drug labeling.
P.L. 111-148: Patient Protection and Affordable Healthcare Act Provisions relating to biosimilar drug products; H.R. 1919 & H.R. 3204 Safeguarding America's Pharmaceuticals Act of 2013; S. 957 The Drug Supply Chain Security Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
APOTEX CORPORATION via BROWN RUDNICK LLP
2013 · fourth_quarter · Q4
S. 504: Fair and Immediate Release of Generic Drugs Act S. 214: Preserve Access to Affordable Generics Act
H.R. 2725: FDA Safety Over Sequestration Act of 2013
PL113-54: Drug Quality and Security Act; Issues relating to Risk Evaluation and Mitigation Strategies and implementation of the Generic Drug User Fee Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2013 · fourth_quarter · Q4
S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
Issues relating to drug and nutrient shortages; P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 232: Medical Device Access and Innovation Protection Act
Issues relating to generic drug labeling; S. 959: The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2013 · fourth_quarter · Q4
Issues relating to diagnostic laboratory testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS via BROWN RUDNICK LLP
2013 · fourth_quarter · RR
H.R. 2725 - FDA Safety over Sequestration Act. Biosimilar implementation -Track and trace legislation
H.R. 2725 - FDA Safety over Sequestration Act. Biosimilar implementation -Track and trace legislation
H.R. 2725 - FDA Safety over Sequestration Act. Biosimilar implementation -Track and trace legislation
APOTEX CORPORATION via BROWN RUDNICK LLP
2013 · third_quarter · Q3
H.R. 3204: The Drug Quality and Safety Act S. 959: The Pharmaceutical Quality, Security and Accountability Act
S. 504: Fair and Immediate Release of Generic Drugs Act S. 214: Preserve Access to Affordable Generics Act Issues relating to Risk Evaluation and Mitigation Strategies and implementation of the Generic Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROCHE DIAGNOSTICS CORPORATION via BROWN RUDNICK LLP
2013 · third_quarter · Q3
Issues relating to diagnostic laboratory testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPIRA, INC. via BROWN RUDNICK LLP
2013 · third_quarter · 3A
-- S. 1413: FDA User Fee Protection Act -- H.R. 2725: "FDA Safety Over Sequestration Act of 2013
Issues relating to prescription drug shortages: --P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products.; --H.R. 1919: Safeguarding America's Pharmaceuticals Act of 2013; --H.R. 3204: The Drug Quality and Safety Act; --S. 957: The Drug Supply Chain Security Act; --S. 232: Medical Device Access and Innovation Protection Act
-- Issues relating to generic drug labeling -- S. 959: The Pharmaceutical Quality, Security and Accountability Act -- H.R. 3204: The Compounding Clarity Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
H.R. 2725 - FDA Safety over Sequestration Act. Biosimilar implementation -Track and trace legislation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office